NO328271B1 - Anvendelse av nitrogeninneholdende heteroarylforbindelser for fremstilling av medikamenter til forebyggelse av amyloidose samt nitrogeninneholdende heteroarylforbindelser egnet for slik anvendelse - Google Patents

Anvendelse av nitrogeninneholdende heteroarylforbindelser for fremstilling av medikamenter til forebyggelse av amyloidose samt nitrogeninneholdende heteroarylforbindelser egnet for slik anvendelse Download PDF

Info

Publication number
NO328271B1
NO328271B1 NO20042709A NO20042709A NO328271B1 NO 328271 B1 NO328271 B1 NO 328271B1 NO 20042709 A NO20042709 A NO 20042709A NO 20042709 A NO20042709 A NO 20042709A NO 328271 B1 NO328271 B1 NO 328271B1
Authority
NO
Norway
Prior art keywords
group
hydrogen atom
alkyl group
bis
diamine
Prior art date
Application number
NO20042709A
Other languages
English (en)
Norwegian (no)
Other versions
NO20042709L (no
Inventor
Isao Kaneko
Kazuo Koyama
Shinji Marumoto
Masaki Meguro
Tomiichiro Oda
Yusuhiro Nakagami
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Publication of NO20042709L publication Critical patent/NO20042709L/no
Publication of NO328271B1 publication Critical patent/NO328271B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
NO20042709A 2001-11-28 2004-06-28 Anvendelse av nitrogeninneholdende heteroarylforbindelser for fremstilling av medikamenter til forebyggelse av amyloidose samt nitrogeninneholdende heteroarylforbindelser egnet for slik anvendelse NO328271B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001361847 2001-11-28
JP2002192777 2002-07-02
PCT/JP2002/012265 WO2003045923A1 (en) 2001-11-28 2002-11-25 Preventives or remedies for alzheimer’s disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds

Publications (2)

Publication Number Publication Date
NO20042709L NO20042709L (no) 2004-08-27
NO328271B1 true NO328271B1 (no) 2010-01-18

Family

ID=26624724

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042709A NO328271B1 (no) 2001-11-28 2004-06-28 Anvendelse av nitrogeninneholdende heteroarylforbindelser for fremstilling av medikamenter til forebyggelse av amyloidose samt nitrogeninneholdende heteroarylforbindelser egnet for slik anvendelse

Country Status (21)

Country Link
US (6) US7589105B2 (ja)
EP (1) EP1473289B1 (ja)
JP (1) JP4490690B2 (ja)
KR (1) KR101031720B1 (ja)
CN (1) CN100354267C (ja)
AT (1) ATE438629T1 (ja)
AU (1) AU2002349480B2 (ja)
BR (1) BR0214539A (ja)
CA (1) CA2468948C (ja)
DE (1) DE60233266D1 (ja)
DK (1) DK1473289T3 (ja)
ES (1) ES2330090T3 (ja)
HK (1) HK1070371A1 (ja)
HU (1) HUP0402657A3 (ja)
IL (2) IL162210A0 (ja)
MX (1) MXPA04005027A (ja)
NO (1) NO328271B1 (ja)
NZ (1) NZ533147A (ja)
PL (1) PL370531A1 (ja)
TW (1) TW200300688A (ja)
WO (1) WO2003045923A1 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP2316459B1 (en) * 2002-07-29 2013-11-06 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
WO2005003103A2 (en) * 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
PT1656372E (pt) 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
WO2006068770A1 (en) 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
CA2591948C (en) 2005-01-19 2013-11-12 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
CN101184493A (zh) * 2005-03-04 2008-05-21 阿尔斯根公司 用乙胺嘧啶及类似物治疗肌萎缩性侧索硬化
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
GB0608386D0 (en) * 2006-04-27 2006-06-07 Senexis Ltd Compounds
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
US7982036B2 (en) 2007-10-19 2011-07-19 Avila Therapeutics, Inc. 4,6-disubstitued pyrimidines useful as kinase inhibitors
US8393968B2 (en) * 2008-09-03 2013-03-12 Igt Gaming system, gaming device and method for providing a strategy game having a plurality of awards
US8210935B2 (en) * 2008-11-12 2012-07-03 Igt Gaming system, gaming device and method of providing collectors and tokens associated with collectors
US8287364B2 (en) * 2008-11-13 2012-10-16 Igt Gaming system, gaming device, and method for providing a game in which a player collects emblems by positioning accumulators in a field
KR101095026B1 (ko) * 2009-01-23 2011-12-20 한국과학기술연구원 비스(스티릴)피리미딘 및 비스(스티릴)벤젠 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
CN102706839B (zh) * 2011-01-31 2015-08-12 香港科技大学 水溶性aie发光剂及其在检测和延迟淀粉样蛋白质的淀粉样纤维化中的用途
IN2014MN00381A (ja) * 2011-08-04 2015-06-19 Colourtex Ind Ltd
US10538516B2 (en) 2015-03-25 2020-01-21 National Center For Geriatrics And Gerontology Oxadiazole derivative and pharmaceutical containing same
WO2017106367A1 (en) * 2015-12-15 2017-06-22 D.E. Shaw Research, Llc Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2393755A (en) * 1942-08-05 1946-01-29 Gen Electric Method of preparing hydroxyarylamino triazines
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
FR2720638B1 (fr) * 1994-06-03 1997-04-04 Oreal Compositions cosmétiques antisolaires à base d'un mélange synergétique de filtres et utilisations.
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
WO1998052551A1 (fr) * 1997-05-22 1998-11-26 Kyowa Hakko Kogyo Co., Ltd. Composes bisaryle et remedes contre le cancer contenant ces composes
US6335339B1 (en) * 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
ATE342892T1 (de) * 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
ES2270612T3 (es) * 1998-08-29 2007-04-01 Astrazeneca Ab Compuestos de pirimidina.
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
WO2001055093A1 (fr) 2000-01-25 2001-08-02 Japan Tobacco Inc. Composes a base de n-arylhydrazide et leur utilisation en tant que medicaments
JP2002145840A (ja) * 2000-01-25 2002-05-22 Japan Tobacco Inc Ｎ−アリールヒドラジド化合物及びその医薬用途
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds

Also Published As

Publication number Publication date
CA2468948A1 (en) 2003-06-05
KR20040068170A (ko) 2004-07-30
AU2002349480B2 (en) 2008-10-30
IL162210A (en) 2012-08-30
US8003645B2 (en) 2011-08-23
EP1473289B1 (en) 2009-08-05
US20110275640A1 (en) 2011-11-10
DE60233266D1 (de) 2009-09-17
CN1596246A (zh) 2005-03-16
JPWO2003045923A1 (ja) 2005-04-07
KR101031720B1 (ko) 2011-04-29
NZ533147A (en) 2006-12-22
TW200300688A (en) 2003-06-16
WO2003045923A1 (en) 2003-06-05
ES2330090T3 (es) 2009-12-04
MXPA04005027A (es) 2004-08-11
US20110275641A1 (en) 2011-11-10
CN100354267C (zh) 2007-12-12
US20090286794A1 (en) 2009-11-19
CA2468948C (en) 2012-04-17
ATE438629T1 (de) 2009-08-15
NO20042709L (no) 2004-08-27
HUP0402657A3 (en) 2010-03-29
US7589105B2 (en) 2009-09-15
US20090286809A1 (en) 2009-11-19
HUP0402657A2 (hu) 2005-03-29
US20080182846A1 (en) 2008-07-31
HK1070371A1 (en) 2005-06-17
DK1473289T3 (da) 2009-11-30
US20050054732A1 (en) 2005-03-10
AU2002349480A1 (en) 2003-06-10
IL162210A0 (en) 2005-11-20
BR0214539A (pt) 2004-11-03
PL370531A1 (en) 2005-05-30
EP1473289A4 (en) 2005-11-23
EP1473289A1 (en) 2004-11-03
JP4490690B2 (ja) 2010-06-30

Similar Documents

Publication Publication Date Title
NO328271B1 (no) Anvendelse av nitrogeninneholdende heteroarylforbindelser for fremstilling av medikamenter til forebyggelse av amyloidose samt nitrogeninneholdende heteroarylforbindelser egnet for slik anvendelse
CN104812749B (zh) 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物
US7671063B2 (en) 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors
US9199945B2 (en) Cycloalkyl-substituted pyrimidinedione compounds
AU2010323227B2 (en) Method for producing methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate and its purification for use thereof as pharmaceutical substance
KR100926842B1 (ko) 11-베타-ｈｓｄ1 억제제로서의 아릴-피리딘 유도체
US8735412B2 (en) Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine
KR20220020410A (ko) 심장 상태에 대한 피리미딘디온 화합물
TW200946522A (en) BACE inhibitors
SK278444B6 (en) Substituted 5-arylpyrimidine, manufacturing process thereof and pharmaceutical composition containing its
EP3135667A1 (en) Novel 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof
KR20110002465A (ko) 세포 보호 작용을 갖는 피리미딘 유도체 및 그 용도
KR101379808B1 (ko) 산화질소 생성 억제용 피라졸로피리미딘 유도체 화합물
JP3107784B2 (ja) 光学活性ピペリジン誘導体の酸付加塩及びその製法
WO2008129069A1 (en) Inhibitors of protein kinases
DK156722B (da) Analogifremgangsmaade til fremstilling af 2-piperazinopyrimidinderivater
EP1390351B1 (en) Pyrimidine derivatives useful as selective cox-2 inhibitors
EP1136486A1 (en) 2-[Indanylamino]pyrimidone and 2-[tetrahydronaphthalenylamino]pyrimidone derivatives
US20060173023A1 (en) 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation
Jonak et al. Effect of the substituent at C-6 on the biological activity of 2, 4-diamino-5-(1-adamantyl) pyrimidines
JP2004083547A (ja) 含窒素芳香複素環化合物を含有するアルツハイマー病の予防薬若しくは治療薬又はアミロイド蛋白線維化抑制剤
EP2137164B1 (en) Inhibitors of protein kinases
WO2023238064A1 (en) Chemical compounds
EP1136491A1 (en) 2-[(Heteroaryl)alkylamino]pyrimidone derivatives
CZ324199A3 (cs) Léčivo k zabránění růstu solidního tumoru u člověka a způsob jeho výroby

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees